Protocol Ledger

NCT07126236 · Phase II · RECRUITING

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Interventional Phase II clinical trial protocol NCT07126236 sponsored by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-04 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07126236
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07126236
Protocol FieldVerified Registry Value
NCT IdentifierNCT07126236
Consolidated Lead SponsorGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07126236
Hospital Research SiteLocationSite Profile
Hospital Universitario Virgen del RocíoSeville, SpainOpen Hospital Dossier ->
Hospital Universitario Miguel ServetZaragoza, SpainOpen Hospital Dossier ->
Hospital Universitario de SalamancaSalamanca, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI